Published • loading... • Updated
New hope for breast cancer patients as life-extending drug now on NHS in England
The NHS will now cover Enhertu for about 1,000 women after a commercial deal and revised cost-effectiveness rules cleared the drug.
- On Thursday, the National Institute for Health and Care Excellence confirmed Enhertu is now available for roughly 1,000 women in England with HER2-low metastatic breast cancer following a newly agreed "commercial solution."
- NICE reversed its 2024 rejection after a UK-USA trade deal increased the cost-effectiveness threshold per Quality-Adjusted Life Year from £30,000 to £35,000, alongside new quality-of-life assessment methods introduced in August.
- Patient Paula Van Santen, 51, from Banbury, described the approval as a "new sense of hope," as Enhertu can extend life by nearly seven months on average, with some patients living up to three years longer.
- Health Secretary Yvette Cooper called the decision "life-changing," while Breast Cancer Now chief executive Claire Rowney noted the delay caused "devastating cost" for patients who missed treatment opportunities.
- AstraZeneca UK country president Tom Keith-Roach stated the milestone aligns England with Scotland and 26 other European countries, while officials now look to Wales and Northern Ireland to expand availability.
Insights by Ground AI
17 Articles
17 Articles
GB NewsReposted by 
PressNewsAgency
PressNewsAgencyNHS reaches deal to roll out life-extending breast cancer drug after years of arguing over cost
A breakthrough breast cancer treatment manufactured by AstraZeneca has been approved for use on the NHS in England, following years of dispute over its price. The National Institute for Health and Care Excellence gave the green light to Enhertu yesterday evening, making it available to patients from Thursday.Around a thousand women annually living with incurable metastatic breast cancer stand to benefit from the drug, which on average extends li…
·London, United Kingdom
Read Full Article
Coverage Details
Total News Sources17
Leaning Left3Leaning Right4Center5Last UpdatedBias Distribution42% Center
Bias Distribution
- 42% of the sources are Center
42% Center
L 25%
C 42%
R 33%
Factuality
To view factuality data please Upgrade to Premium
